New pill could ease endometriosis pain without needles
NCT ID NCT07015268
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests an oral drug called KLH-2109 for pelvic pain in 288 women with endometriosis. Participants receive either KLH-2109 or a standard injection (leuprorelin acetate) for 12 weeks. The goal is to see if the new pill works as well as the injection in reducing daily pain scores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KLH-2109 (oral tablet)
- What this could lead to
- If successful, KLH-2109 could offer a new oral option to ease pelvic pain from endometriosis, potentially with fewer side effects than current injections.
- What could go wrong
- This is a mid-stage trial with 288 participants, so results may not apply to everyone. The drug is compared to an existing treatment, and it may not prove as effective or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can yoga ease the pain of endometriosis after surgery?
- Building a biological treasure trove to decode Women's health mysteries
- Gaming for health: could a video game empower endometriosis patients?
- Can a new formulation of an endometriosis drug match the standard?
- Can a glowing dye reveal a Woman's fertility after ovarian cyst surgery?
- Can we predict endometriosis recurrence and fertility outcomes?